Classics In Chemical Neuroscience: Fluoxetine (Prozac)
DOI:
https://doi.org/10.61841/9hjv1907Keywords:
depression, SSRI, serotonin, fluoxetine, Prozac, antidepressantAbstract
The first significant advancement in the treatment of depression since the development of monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs) about thirty years prior was the release of fluoxetine (Prozac). Compared to TCAs and MAOIs, it had less side effects and was the first selective serotonin reuptake inhibitor (SSRI) to be licensed by the US Food and Drug Administration. The precise method by which fluoxetine's clinical efficacy manifests is still up for debate, but there is no denying the significance of fluoxetine and similar SSRIs to the field. The brand name Prozac has become widely known, contributing to the reduction of long-standing stigmas attached to depression and increasing public understanding of the condition. The synthesis, pharmacology, drug metabolism, side effects, and history of fluoxetine will all be covered in this review, along with its significance for depression treatment and neuroscience in general.
Downloads
References
1. For up-to date information on depression from the National Institute of Mental Health, see: www.nimh.nih.gov/health/topics/ depression.
2. Smith, K. (2011) Trillion dollar brain drain. Nature 478, 5−8.
3. Artigas, F. (2013) Future directions for serotonin and antidepressants. ACS Chem. Neurosci. 4, 5−8.
4. American Psychiatric Association. (2013) Diagnostic and Statistical Manual of Mental Disorders, 5th ed., American Psychiatric Press, Washington, DC.
5. Lader, M. H. (1998) The Management of Depression (Checkley, S., Ed.), pp 18−211, Blackwell Press, Oxford, U.K.
6. Glennon, R. A., and Iversen, L. (2010) Antidepressants. In Burger’s Medicinal Chemistry, Drug Discovery and Development: CNS Disorders (Abraham, D. J., Rotella, D. P., Eds.), 7th ed., pp 219−264, John Wiley & Sons, Hoboken, NJ.
7. Kessler, R. C., Chiu, W. T., Demler, O., and Walter, M. S. (2005) Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 62, 617−627.
8. Sullivan, P. F., Neale, M. C., and Kendler, K. S. (2000) Genetic epidemiology of major depression: review and meta- analysis. Am. J. Psychiatry 157, 1552−1562.
9. Moret, C., and Briley, M. (1992) Effect of antidepressant drugs on monamine synthesis in brain in vivo. Neuropharmacology 31, 679− 684.
10. Culpepper, L. (2010) Why do you need to move beyond firstline therapy for major depression? J. Clin. Psychiatry 71, 4−9.
11. Hodes, G. E., and Russo, S. J. (2012) The neurobiology of depression and anxiety: how do we change from models of drug efficacy to understanding mood and anxiety disorders? In Drug Discovery for Psychiatric Disorders (Rankovic, Z., Bingham, M., Nestler, E. J., and Hargreaves, R., Eds.), pp 159−183, The Royal Society of Chemistry, Cambridge, U.K.
12. Metzner, R. J. (2013) The impact of neurochemical mediators on antidepressant effectiveness. ACS Chem. Neurosci. 4, 1245−1248.
13. Gelenberg, A. G., Freeman, M. P., Markowitz, J. C., Rosenbaum, J. F., Thase, M. E., Trivedi, M. H., and Van Rhoads,
R. S. (2010) Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third ed., American Psychiatric Association, Arlington, VA.
14. For societal and workplace impact of depression, see: www. caremanagementfordepression.org.
15. Bernois, G. E. (1998) Melancholia and depression during the 19th century: A conceptual history. Br. J. Psych. 153, 298−304.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
